{'fraction_non_alphanumeric': 0.03170028818443804, 'fraction_numerical': 0.02881844380403458, 'mean_word_length': 5.261261261261262, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial

Bleomycin was administered in a phase II trial to 10 patients with malignant ascities. Complete responses to intraperitoneal bleomycin were observed in 6/10 patients (60%). Pharmacokinetics of serum and intraperitoneal bleomycin showed peak levels at 15 minutes with a peritoneal fluid half‐life of 4.2 ± 0.1 hours and a serum half‐life of 5.0 ± 1.2 hours. There was a 400‐fold difference in concentration when bleomycin was administered intra‐abdominally. Toxicities with intraperitoneal bleomycin were minimal. This phase II trial confirms the efficacy of intraperitoneal bleomycin; further trials appear warranted.